Virender Verma1*, Priya Soni2, Sanjiv Nanda3, Anjani Kumar1, Vivek Nandan4, Shanu Prabhakar4 and Joshi Anand K5
1Consultant Pediatrician and Neonatal Intensivist, Ruban Hospital, Patna, India
2Consultant Emergency Physician, Ruban Hospital, Patna, India
3Senior Prof Pediatrics, PGIMS, Rohtak, India
4Senior Residents Pediatrics, Ruban Hospital, Patna, India
5Senior Consultant Pediatrics and Neonatology, The Mission Hospital, Durgapur, India
*Corresponding Author: Virender Verma, Consultant Pediatrics and Neonatology, Lead: Pediatric Intensive Care, Ruban Hospital, Patna, India.
Received: December 23, 2019; Published: December 31, 2019
Persistent pulmonary hypertension of newborn (PPHN) is a common problem encountered in neonatal intensive care units. The problem arise because of failure of smooth transition from fetal circulation to post-natal circulation after birth. This causes hypoxemia due to high resistance in pulmonary vasculature causing impediment into normal pulmonary blood flow apparently causing right – to – left shunt.
The problem is more commonly associated with fullterm neonates and there are a number of therapies available to manage the problem. This article discusses the evidence based approach towards the pharmacological management of persistent pulmonary hypertension of newborn.
Keywords:Persistent Pulmonary Hypertension of Newborn; PPHN; Pharmacological Management; Neonate; NICU; Newborn; Hypoxia; Neonatal Ventilator Dependency; iNO; Inhaled Nitric Oxide; Pulmonary Hypertension
Citation: Virender Verma., et al. “Evidence Based Practice towards Pharmacological Management of Persistent Pulmonary Hypertension of Newborn in Neonatal Intensive Care Unit”.Acta Scientific Pharmacology 1.1 (2020): 20-24.
Copyright: © 2020 Virender Verma., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.